Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex

Pharmacokinetic features of dolutegravir with rifampicin and rifabutin among patients coinfected with human immunodeficiency virus and tuberculosis/mycobacterium avium complex

Background: Rifamycins are the cornerstone of anti-tuberculosis therapy while they are potent inducers of drug metabolizing enzymes. For the first time, we evaluated the effect of rifampicin (RIF) and rifabutin (RBT) on the pharmacokinetics (PK) of dolutegravir (DTG) in patients with HIV and tubercu...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiaoqin Le, Xiaoye Guo, Jianjun Sun, Li Liu, Yinzhong Shen, Jiangrong Wang, Tangkai Qi, Zhenyan Wang, Yang Tang, Wei Song, Lin Yin, Lijun Zhang, Renfang Zhang, Jun Chen
Formato: Artículo
Lenguaje:English
Publicado: Elsevier 2022-03-01
Colección:International Journal of Infectious Diseases
Materias:
HIV
tuberculosis
pharmacokinetics
dolutegravir
rifampicin
rifabutin
Acceso en línea:http://www.sciencedirect.com/science/article/pii/S1201971222000029

Internet

http://www.sciencedirect.com/science/article/pii/S1201971222000029

Ejemplares similares